Streetbeat News

Analyst Ratings

NVDA

Raymond James analyst Srini Pajjuri has maintained a Strong Buy rating on Nvidia Corp (NASDAQ:NVDA) and increased the price target from $600 to $700. Pajjuri highlights Nvidia's unchallenged position in Gen AI infrastructure and anticipates strong double-digit revenue growth. The growth is expected from new GPU ramps and expansion into restricted markets like China. Despite potential risks from customer spending pauses and competition, the analyst believes Nvidia's software moat and AI demand will minimize impact. Nvidia's PC Gaming business is strong, and expansion into ARM PC processors is likely. The analyst projects FY23 revenue and EPS at $58.83 billion and $11.08, respectively, and notes the valuation already accounts for a potential digestion period. NVDA shares were up 3.43% at $590.65.

Portfolio Pulse from Anusuya Lahiri

January 19, 2024 | 8:04 pm

MTN

Truist Securities analyst Patrick Scholes has reiterated a Buy rating on Vail Resorts (NYSE:MTN) and maintained a $290 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 8:03 pm

HUM

Truist Securities analyst David Macdonald has reiterated a Hold rating on Humana (NYSE:HUM) and maintained a $550 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 8:01 pm

PH

Parker Hannifin (NYSE:PH) has received varied analyst ratings over the past three months, with a recent shift towards a more bullish sentiment. The average 12-month price target has increased to $513.4, with a high estimate of $551.00 and a low of $500.00. Analysts from Stifel, Goldman Sachs, Wells Fargo, and Deutsche Bank have maintained or raised their price targets, reflecting positive expectations for the company's performance. Parker Hannifin's financials show strong revenue growth and net margin, but challenges in asset utilization and debt management.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 8:00 pm

PPG

PPG Industries (NYSE:PPG) received mixed analyst ratings over the past three months, with an average 12-month price target of $159.75, up from $157.00. Analysts from Baird, UBS, Wells Fargo, and Keybanc have provided ratings and adjusted price targets, reflecting a positive outlook on PPG's financial performance, which includes strong revenue growth, net margin, ROE, ROA, and a healthy debt-to-equity ratio. PPG is a leading global producer of coatings with a significant market presence.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 8:00 pm

AVY

Avery Dennison (NYSE:AVY) has received mixed analyst ratings over the past three months, with a total of 5 bullish, 1 indifferent, and 1 somewhat bearish ratings. The average 12-month price target for AVY has been raised to $224.00, up from the previous $211.50, with a high estimate of $249.00 and a low of $208.00. Analysts from firms including Truist Securities, UBS, Citigroup, and B of A Securities have updated their ratings and price targets, reflecting changes in market conditions and company performance. Avery Dennison's financials show a market cap above industry average, a revenue decline of -9.44% as of September 30, 2023, a high net margin of 6.59%, an ROE of 6.78%, an ROA of 1.69%, and a low debt-to-equity ratio of 1.61.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 8:00 pm

AVY

Truist Securities analyst Michael Roxland has reiterated a Buy rating on Avery Dennison (NYSE:AVY) and maintained a price target of $249.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 8:00 pm

JBHT

Stifel analyst J. Bruce Chan has reiterated a Hold rating on JB Hunt Transport Services (NASDAQ:JBHT) and maintained a price target of $188.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 7:58 pm

PH

Stifel analyst Nathan Jones has reiterated a Buy rating on Parker Hannifin (NYSE:PH) and maintained a $500 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 7:56 pm

BMY

IKNA

Ikena Oncology Inc (NASDAQ:IKNA) is streamlining its organization to focus on its key oncology clinical programs, IK-930 and IK-595, leading to a 35% workforce reduction. With $175 million in cash, the company's financial runway is extended to the second half of 2026. Wedbush maintains an Outperform rating with a price target of $8, while William Blair also maintains an Outperform rating. Bristol-Myers Squibb (NYSE:BMY) has opted out of developing IK-175 and IK-412, with Ikena regaining full rights but not planning further investment in these programs. IKNA shares dropped 11.6% to $1.45.

Portfolio Pulse from Vandana Singh

January 19, 2024 | 7:55 pm